ARTICLE | Financial News
Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets
July 17, 2019 10:34 PM UTC
Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round.
Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and angel investors, including the University of Chicago Startup Investment Program, also participated in the round for Pyxis Oncology Inc. (Boston, Mass.), which in addition to Gajewski counts Longwood and life sciences executive and investor John Flavin as co-founders...